[go: up one dir, main page]

ATE332134T1 - Hautpenetrationsförderer - Google Patents

Hautpenetrationsförderer

Info

Publication number
ATE332134T1
ATE332134T1 AT98952860T AT98952860T ATE332134T1 AT E332134 T1 ATE332134 T1 AT E332134T1 AT 98952860 T AT98952860 T AT 98952860T AT 98952860 T AT98952860 T AT 98952860T AT E332134 T1 ATE332134 T1 AT E332134T1
Authority
AT
Austria
Prior art keywords
skin penetration
penetration promoter
promoter
skin
penetration
Prior art date
Application number
AT98952860T
Other languages
English (en)
Inventor
Anthony David Ormerod
Arthur Winfield
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE332134T1 publication Critical patent/ATE332134T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
AT98952860T 1997-11-07 1998-11-05 Hautpenetrationsförderer ATE332134T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723669.9A GB9723669D0 (en) 1997-11-07 1997-11-07 Skin penetration enhancing components

Publications (1)

Publication Number Publication Date
ATE332134T1 true ATE332134T1 (de) 2006-07-15

Family

ID=10821813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98952860T ATE332134T1 (de) 1997-11-07 1998-11-05 Hautpenetrationsförderer

Country Status (33)

Country Link
US (2) US6958153B1 (de)
EP (2) EP1632231A3 (de)
JP (1) JP2001522801A (de)
KR (1) KR20010031741A (de)
CN (1) CN1115148C (de)
AR (1) AR014011A1 (de)
AT (1) ATE332134T1 (de)
AU (1) AU759326B2 (de)
BG (1) BG104370A (de)
BR (1) BR9815264A (de)
CA (1) CA2309159C (de)
CY (1) CY1105243T1 (de)
DE (1) DE69835163T2 (de)
DK (1) DK1028727T3 (de)
EA (1) EA003616B1 (de)
EE (1) EE04390B1 (de)
ES (1) ES2268795T3 (de)
GB (1) GB9723669D0 (de)
GE (2) GEP20043171B (de)
HR (1) HRP20000233A2 (de)
HU (1) HUP0003675A3 (de)
ID (1) ID24662A (de)
IL (1) IL135978A0 (de)
NO (1) NO20002078L (de)
NZ (3) NZ504076A (de)
PL (1) PL340710A1 (de)
PT (1) PT1028727E (de)
SK (1) SK6622000A3 (de)
TR (1) TR200001238T2 (de)
TW (1) TW557218B (de)
UA (1) UA73274C2 (de)
WO (1) WO1999024036A1 (de)
ZA (1) ZA9810111B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1133987A1 (de) * 2000-03-09 2001-09-19 Ian Whitcroft Behandlung von entzündlichen Dermatosen mit Erythromycin oder Clarithromycin, Metronidazol und einem Wasserstoffpumpehemmer
WO2001066117A1 (en) * 2000-03-09 2001-09-13 Ian Andrew Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
ES2325951T3 (es) 2001-08-29 2009-09-25 Pharmakodex Limited Dispositivo de administracion topica.
AU2002347541A1 (en) * 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Stable topical formulation of clarithromycin
ATE426414T1 (de) * 2002-05-15 2009-04-15 Endocyte Inc Vitamin-mitomycin-konjugate
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
EP1594484A2 (de) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmazeutisches pflaster
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20070154966A1 (en) * 2003-12-29 2007-07-05 Ronit Sagi-Eisenberg Assay for the detection of rapamycin and rapamycin analogs
EP1789391B1 (de) 2004-07-23 2017-06-28 Endocyte, Inc. Zweiwertige linker und konjugate davon
BRPI0515378A (pt) * 2004-09-16 2008-07-22 Bayer Healthcare Ag formulações dermalmente aplicáveis para tratamento de doenças de pele em animais
EP3025704B1 (de) * 2005-03-10 2019-01-16 3M Innovative Properties Company Verfahren zur verringerung von mikrobieller kontamination
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
CA2617660C (en) 2005-08-19 2014-03-25 Endocyte, Inc. Multi-drug ligand conjugates
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3569251A1 (de) * 2007-06-25 2019-11-20 Endocyte, Inc. Konjugate mit hydrophilen spacern/linkern
WO2009018447A2 (en) 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2308468A1 (de) * 2009-10-08 2011-04-13 Novaliq GmbH Neuartige pharmazeutische Zusammensetzung mit einem Makrolid-Immunosuppressivum
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
EP2515652A4 (de) * 2009-12-21 2014-11-26 B C Unlimited Liability Company Zusammensetzungen und verfahren zur behandlung von vitiligo
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (de) 2012-10-16 2016-07-13 Endocyte Inc Wirkstofffreisetzungskonjugate mit unnatürlichen aminosäuren und verfahren zur verwendung
ES2797376T3 (es) * 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
JPWO2015199248A1 (ja) * 2014-06-26 2017-04-27 国立大学法人大阪大学 発汗抑制剤
CN108348508A (zh) 2015-09-24 2018-07-31 德雷克塞尔大学 治疗或预防皮肤障碍的新型组合物和方法
FR3050206B1 (fr) 2016-04-15 2018-05-11 Engie Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
CN109689053A (zh) 2016-08-10 2019-04-26 得克萨斯州大学系统董事会 局部雷帕霉素疗法
EP3565520A4 (de) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
CN116056687A (zh) 2020-03-02 2023-05-02 上海奥科达医药科技股份有限公司 含有mtor抑制剂的外用制剂
FR3112537B1 (fr) 2020-07-14 2023-03-31 Engie Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31769A (en) * 1861-03-26 Water-elevator
US3376646A (en) * 1967-03-30 1968-04-09 Herman E. Radke Template tracer
US4335115A (en) 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
ES2136105T3 (es) 1992-08-04 1999-11-16 Rhone Poulenc Rorer Gmbh Preparacion farmaceutica y/o cosmetica.
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi) 1993-02-01 1994-03-10 Pauli Groenberg Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
JPH08133979A (ja) * 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
AU714254B2 (en) * 1994-10-26 1999-12-23 Novartis Ag Pharmaceutical compositions
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use

Also Published As

Publication number Publication date
TW557218B (en) 2003-10-11
ID24662A (id) 2000-07-27
GEP20043171B (en) 2004-02-25
NO20002078L (no) 2000-07-06
US6958153B1 (en) 2005-10-25
AU759326B2 (en) 2003-04-10
TR200001238T2 (tr) 2001-01-22
BG104370A (en) 2000-12-29
EE200000279A (et) 2001-10-15
NZ504076A (en) 2002-12-20
EP1632231A2 (de) 2006-03-08
ZA9810111B (en) 1999-05-07
AU1040899A (en) 1999-05-31
SK6622000A3 (en) 2001-01-18
NZ530752A (en) 2005-05-27
CN1278173A (zh) 2000-12-27
DK1028727T3 (da) 2006-10-23
NZ520449A (en) 2004-04-30
KR20010031741A (ko) 2001-04-16
HUP0003675A3 (en) 2001-05-28
ES2268795T3 (es) 2007-03-16
WO1999024036A1 (en) 1999-05-20
DE69835163D1 (de) 2006-08-17
UA73274C2 (en) 2005-07-15
CA2309159C (en) 2009-03-17
HRP20000233A2 (en) 2001-02-28
EE04390B1 (et) 2004-12-15
EP1028727A1 (de) 2000-08-23
EP1632231A3 (de) 2008-01-23
EP1028727B1 (de) 2006-07-05
PT1028727E (pt) 2006-11-30
US20050239724A1 (en) 2005-10-27
EA003616B1 (ru) 2003-08-28
HUP0003675A2 (hu) 2001-04-28
CA2309159A1 (en) 1999-05-20
EA200000461A1 (ru) 2000-10-30
NO20002078D0 (no) 2000-04-19
GEP20032884B (en) 2003-02-25
CN1115148C (zh) 2003-07-23
CY1105243T1 (el) 2010-03-03
IL135978A0 (en) 2001-05-20
DE69835163T2 (de) 2007-05-31
BR9815264A (pt) 2001-08-14
GB9723669D0 (en) 1998-01-07
JP2001522801A (ja) 2001-11-20
AR014011A1 (es) 2001-01-31
PL340710A1 (en) 2001-02-26

Similar Documents

Publication Publication Date Title
ATE332134T1 (de) Hautpenetrationsförderer
DE69720813D1 (de) Förderer
DE69823277T2 (de) Ablationskatheter
DE69829554D1 (de) Ovalgefortme herzkanüle
ID24118A (id) Terapi gabungan
DE69833417D1 (de) Servo-Schreibkopf
DE69830555D1 (de) Aufnahmekopf
DE69824170D1 (de) Ratenstabilisierender herzschrittmacher
ID24275A (id) Terapi kombinasi
DE59807782D1 (de) Punktionsset
DE69820860D1 (de) Herzschrittmacher
ID16297A (id) Promoter
DK94897A (da) Propeller
DK0926985T3 (da) Forbedringer vedrørende hudpunkteringsapparater
DE69719923D1 (de) Förderer
DE69833493D1 (de) Gewebe
NO983113L (no) Propulsjonsenhet
DE69836690D1 (de) Herzschrittmacher
DE59812959D1 (de) Herzstimulator
DE69812288D1 (de) Förderer
DE59506751D1 (de) Penetrationshilfsmittel
ES1042143Y (es) Construccion de cabina
NO980711L (no) Komponent i hudpleiemiddel
DE69717942D1 (de) Fahrzeugkabine
KR980000116U (ko) 발광등 부자

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028727

Country of ref document: EP

REN Ceased due to non-payment of the annual fee